Bain Capital & Coeptis Therapeutics Holdings

Bain Capital: Bain Capital, LP is accused of orchestrating a secondary stock offering of Coeptis Therapeutics Holdings at a deeply discounted price, allowing it to increase its position before the undisclosed acquisition by AbbVie Inc., resulting in a $120 million windfall.

Coeptis Therapeutics Holdings: Coeptis Therapeutics Holdings is the primary defendant in the class action lawsuit, accused of making false and misleading statements regarding a secondary stock offering and its subsequent acquisition by AbbVie Inc.

Bain Capital: Bain Capital, as Coeptis Therapeutics Holdings' controlling shareholder, is accused of acquiring Coeptis Therapeutics Holdings shares at an artificially depressed price while allegedly possessing material nonpublic information about AbbVie Inc.'s acquisition interest, resulting in a significant windfall.

Coeptis Therapeutics Holdings: Coeptis Therapeutics Holdings is the target of a class action lawsuit alleging that its secondary stock offering and proxy statement omitted material facts regarding AbbVie Inc.'s interest in acquiring it, leading to an artificially deflated stock price.

Bain Capital: Bain Capital, Coeptis Therapeutics Holdings's controlling shareholder, acquired shares at an allegedly artificially depressed price during the October Offering while in possession of material nonpublic information about AbbVie Inc.'s interest, leading to a $120 million windfall.

Coeptis Therapeutics Holdings: Coeptis Therapeutics Holdings is the target of a class action lawsuit alleging securities fraud for omitting material facts regarding AbbVie Inc.'s acquisition interest, which artificially deflated its stock price during an offering.